Ar hyn bryd rydym yn gwario dros £21m y flwyddyn ar feddyginiaethau trwyddedig i drin dirywiad macwlaidd gwlyb. Pe bai nifer sylweddol o gleifion yn cael eu trin â  bevacizumab, byddai'r Gwasanaeth Iechyd Gwladol yng Nghymru'n arbed cryn dipyn o arian y gellid ei ailfuddsoddi i drin mwy o gleifion.
The Welsh Government takes access to medicines very seriously; in 2015 we invested £16m to ensure treatment for wet AMD was available promptly and consistently across Wales.  Our £80m New Treatment Fund is ensuring medicines recommended by NICE and the All Wales Medicines Strategy Group are available to patients in Wales faster than ever before.  I am very supportive of the important role the pharmaceutical industry has in developing innovative medicines to market; however, I am pleased with the finding of this case that the pharmaceutical industry cannot have unbounded power to decide which medicines are made available for which purposes.